-
Publisher Of
-
Polyreactive IgM initiates complement activation by PF4/heparin complexes through the classical pathway.
Blood.
132:2431-2440.
2018
-
Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era.
Blood.
129:1763-1767.
2017
-
Incidence of Pediatric VTE in Durham County, North Carolina.
Blood.
126.
2015
-
Autopsy-Proven Venous Thromboembolism (VTE): Incidence and Characteristics of Patients Correlated with Clinical Management Prior to Death.
Blood.
124.
2014
-
The Use of Chronic Transfusions in Sickle Cell Disease for Non-Stroke Related Indications.
Blood.
124.
2014
-
Venous Thromboembolism (VTE) Surveillance: Incidence, Characteristics, and Initial Treatment of VTE Patients.
Blood.
124.
2014
-
Suppression of CXCL12 production by bone marrow osteoblasts is a common and critical pathway for cytokine-induced mobilization.
Blood.
114:1331-1339.
2009
-
Does Living Closer to a Medical Care Center Matter in Sickle Cell Disease?.
Blood.
112:323-324.
2008
-
Obstetric and Gynecological History in Sickle Cell Disease Females.
Blood.
112:867-868.
2008
-
Secondary Acute Myeloid Leukemia (sAML) Treated with Amonafide (AS1413) + Cytarabine: Durable Responses in Poor-Risk AML.
Blood.
112:1019-1020.
2008
-
A Phase 2 Study of Actinium-225 (Ac-225)-Lintuzumab in Older Patients with Untreated Acute Myeloid Leukemia (AML) - Interim Analysis of 1.5 mu ci/Kg/Dose.
Blood.
2018
-
Allergic Sensitization Is Associated with Decreased Risk of ED Visits and Hospitalizations for Pain in Sickle Cell Disease.
Blood.
2018
-
Calcium/Calmodulin Dependent Protein Kinase Kinase 2 (CaMKK2) Expressed in the Host Promotes Lymphoma Cells Growth By Controlling Myeloid Derived Suppressor Cells Expansion.
Blood.
2018
-
Disparities in Foundation and Federal Support and Development of New Therapeutics for Sickle Cell Disease and Cystic Fibrosis.
Blood.
2018
-
ET190L1-Artemis (TM) Cell Therapy Results in Durable Disease Remissions with No Cytokine Release Syndrome or Neurotoxicity in Patients with Relapsed and Refractory B-Cell Lymphoma.
Blood.
2018
-
Early Results from a Biomarker-Directed Phase 2 Trial of Sy-1425 in Combination with Azacitidine or Daratumumab in Non-APL Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS).
Blood.
2018
-
End-of-Life Care Quality Outcomes Among Medicare Beneficiaries with Hematologic Malignancies.
Blood.
2018
-
Health Related Quality of Life and Fatigue in Patients with Pyruvate Kinase Deficiency.
Blood.
2018
-
Intestinal Enterococcus Is a Major Risk Factor for the Development of Acute Gvhd.
Blood.
2018
-
Knowledge, Cultural, and Structural Barriers to Thalassemia Screening in Migrant Populations in Thailand.
Blood.
2018
-
Limitations to Receiving Allogeneic Hematopoietic Cell Transplantation for Treatment of Acute Myeloid Leukemia: A Large Multi-Center Prospective Longitudinal Observational Study.
Blood.
2018
-
Loss of Microbiota Diversity after Autologous Stem Cell Transplant Is Comparable to Injury in Allogeneic Stem Cell Transplant.
Blood.
2018
-
Management of Cytokine Release Syndrome in AML Patients Treated with Flotetuzumab, a CD123 x CD3 Bispecific Dart (R) Molecule for T-Cell Redirected Therapy.
Blood.
2018
-
Multicenter Microbiota Analysis Indicates That Pre-HCT Microbiota Injury Is Prevalent across Geography and Predicts Poor Overall Survival.
Blood.
2018
-
Palliative Care Physicians' Views Toward Hematology and the Care of Patients with Hematologic Diseases: Results of a Nationwide Survey.
Blood.
2018
-
Patients' Perspectives on the Definition of Cure in Chronic Myeloid Leukemia: A US Based Survey.
Blood.
2018
-
Pediatric Patient-Reported Symptom Tracking in Oncology (Pedi-PReSTO): A Feasibility Study.
Blood.
2018
-
Phase 1 Cohort Expansion of Flotetuzumab, a CD123xCD3 Bispecific Dart (R) Protein in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML).
Blood.
2018
-
Predictors of Patient-Reported Communication with Their Health Care Team about New Treatment Options for Chronic Lymphocytic Leukemia.
Blood.
2018
-
Rapid and Robust CD4+and CD8+T-, NK-, B- and Monocyte Cell Reconstitution after Nicotinamide-Expanded Cord Blood Transplantation.
Blood.
2018
-
Results of Pivotal Phase 2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN).
Blood.
2018
-
Sleep Disturbance Among Individuals with Multiple Myeloma: The Interplay between Physical and Psychosocial Symptoms.
Blood.
2018
-
Survival Differences Among Patients (pts) with Acute Myeloid Leukemia (AML) Treated with Allogeneic Hematopoietic Cell Transplantation (HCT) Versus Non-HCT Therapies: A Large Real-Time Multi-Center Prospective Longitudinal Observational Study.
Blood.
2018
-
Treatment Decision Making and Treatment Satisfaction Among Individuals Living with Chronic Myeloid Leukemia.
Blood.
2018
-
Treatment with Foscarnet after Allogenic Hematopoietic-Cell Transplant (AlloHCT) Is Associated with Long-Term Loss of Renal Function.
Blood.
2018
-
Updated Analysis of the Efficacy and Safety of Tisagenlecleucel in Pediatric and Young Adult Patients with Relapsed/Refractory (r/r) Acute Lymphoblastic Leukemia.
Blood.
2018
-
Use of a Processed Hematopoietic Stem Cell Product (FCRx) in Unmatched Related and Unrelated Donor - Recipient Pairs Is Associated with High Levels of Donor Chimerism and Donor-Specific Tolerance to Kidney Allografts.
Blood.
2018
-
Acute Lymphoblastic Leukemia Cells Bypass the Blood Brain Barrier to Enter the CNS Via a Neuronal Developmental Pathway.
Blood.
2017
-
Associations between Complete Remissions (CRs) with 7+3 Induction Chemotherapy for Acute Myeloid Leukemia and 2-3 Year Survival ("Potential Cure") over the Past Four Decades: Analysis of SWOG Trial Data.
Blood.
2017
-
Beliefs and Patterns of Practice in the Management of Hyperleukocytosis and Leukostasis Among Health Care Providers for Patients with Acute Leukemia: A Large North American Web-Based Survey.
Blood.
2017
-
Clinical Outcomes of Microtransplantation for Older Adults with Acute Myeloid Leukemia.
Blood.
2017
-
Early Results from a Biomarker-Directed Phase 2 Trial of Sy-1425 in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Demonstrate DHRS3 Induction and Myeloid Differentiation Following Sy-1425 Treatment.
Blood.
2017
-
Evaluation of Residual Disease Positivity Rates in Adult Acute Lymphoblastic Leukemia Patients Treated with Asparaginase Versus Non-Asparaginase Containing Regimens.
Blood.
2017
-
Favorable Outcomes with Fludarabine, High Dose Cytarabine and Granulocyte Colony Stimulating Factor (FLAG) As Re-Induction for Residual Acute Myeloid Leukemia on Day 14 Bone Marrow.
Blood.
2017
-
Financial Burden and Patient-Reported Outcomes after Hematopoietic Cell Transplantation: Impact of Pre-Treatment Awareness of Transplant-Associated Costs.
Blood.
2017
-
IMGN779, a Next-Generation CD33-Targeting Antibody-Drug Conjugate (ADC) Demonstrates Initial Antileukemia Activity in Patients with Relapsed or Refractory Acute Myeloid Leukemia.
Blood.
2017
-
Insurance Design and Out-of-Pocket (OOP) Costs: a Comparison of Oral and Intravenous (IV) Treatment Plans for Chronic Lymphocytic Leukemia (CLL) in the Era of the Affordable Care Act (ACA).
Blood.
2017
-
Ivosidenib (AG-120) in Mutant IDH1 AML and Advanced Hematologic Malignancies: Results of a Phase 1 Dose Escalation and Expansion Study.
Blood.
2017
-
Multiple Myeloma Symptom Burden, Perceived Control, and Quality of Life: Findings from the Cancer Experience Registry.
Blood.
2017
-
Patient-Reported Distress in Hodgkin Lymphoma Patients on Active Therapy Vs. Long-Term Survivors.
Blood.
2017
-
Patient-Reported Sleep Quality at Baseline Correlates with 1-Year Survival after Allogeneic Hematopoietic Cell Transplantation in Adults.
Blood.
2017
-
Perceptions of Prognosis and Treatment Risk in Older Patients with Acute Myeloid Leukemia.
Blood.
2017
-
Pre-Transfusion Rejuvenation of RBCs for Red Blood Cell Exchange: Report of Feasibility.
Blood.
2017
-
Prospective Study of Acute Myeloid Leukemia (AML) Clinical Epidemiology and Cytogenetic Risk Group in Older Adults in the ECOG-ACRIN E2906 Clinical Trial: The Acute Leukemia Epidemiology, Survival and Endpoints (ALESE) Study.
Blood.
2017
-
RNA-Sequencing of Isolated Cell Populations Expressing Human APOL1 Risk Variants Reveals Molecular Correlates of Sickle Cell Nephropathy in Zebrafish Podocytes.
Blood.
2017
-
Results from Enestgoal: A Phase 2 Study of Treatment-Free Remission (TFR) in Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Switched from Imatinib to Nilotinib.
Blood.
2017
-
Results from the US Life after Stopping TKIs (LAST) Study.
Blood.
2017
-
Role of Glucose Transporter 1 in Graft-Versus-Host Disease and Graft-Versus-Tumor Effect.
Blood.
2017
-
The Effect of Rivaroxaban Exposure and Clinical Risk Factors on Efficacy and Safety Outcomes in Patients with Nonvalvular Atrial Fibrillation.
Blood.
2017
-
Transcript Expression, Intron Retention, and RNA Editing Are Conserved in Human Platelets over a 4 Year Period.
Blood.
2017
-
Transfusion Dependence and Use of Hospice Among Medicare Beneficiaries with Leukemia.
Blood.
2017
-
Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia in Real-World US Practices.
Blood.
2017
-
A Phase 1 Trial of Inotuzumab in Combination with CVP (Cyclophosphamide, Vincristine, Prednisone) for Relapsed/ Refractory CD22+Acute Leukemia (SWOG 1312).
Blood.
2016
-
A Phase 1/2 Study of G-CSF, Cladribine, Cytarabine, and Dose-Escalated Mitoxantrone (G-CLAM) in Adults with Newly Diagnosed Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS).
Blood.
2016
-
A Phase 1b Study of Vadastuximab Talirine As Maintenance and in Combination with Standard Consolidation for Patients with Acute Myeloid Leukemia (AML).
Blood.
2016
-
A Phase 1b Study of Vadastuximab Talirine in Combination with 7+3 Induction Therapy for Patients with Newly Diagnosed Acute Myeloid Leukemia (AML).
Blood.
2016
-
A Prospective Randomized Double Blind Phase 3 Clinical Trial of Anti- T Lymphocyte Globulin (ATLG) to Assess Impact on Chronic Graft-Versus-Host Disease (cGVHD) Free Survival in Patients Undergoing HLA Matched Unrelated Myeloablative Hematopoietic Cell Transplantation (HCT).
Blood.
2016
-
Adult Umbilical Cord Blood Transplantation Using Myeloablative Total Body Irradiation, Fludarabine, and Thiotepa Conditioning.
Blood.
2016
-
All-Trans Retinoic Acid (ATRA) Targets IRF4 Deficient, NOTCH2-Activated B Cells from Chronic Gvhd Patients.
Blood.
2016
-
Allogeneic Umbilical Cord Blood Infusion for Adults with Ischemic Stroke (CoBIS): Clinical Outcomes from a Phase 1 Safety Study.
Blood.
2016
-
Analysis of a Global Registration Trial of the Efficacy and Safety of CTL019 in Pediatric and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL).
Blood.
2016
-
Cell-Free DNA Is Elevated after Acute Arterial Injury in Infants.
Blood.
2016
-
Clinical Characteristics and Quality of Life of Children with ITP Starting Second Line Treatments: Data from the ITP Consortium of North America ICON1 Study.
Blood.
2016
-
Clinical Characteristics of Hyposecretory Multiple Myeloma (Monoclonal Immunoglobulin < 3 g/dl) in Afro-Caribbean Patients at a Single Urban Institution.
Blood.
2016
-
Comparable Outcomes of Patients Eligible Versus Ineligible for Southwest Oncology Group (SWOG) Leukemia Studies.
Blood.
2016
-
Complete Remissions (CRs) with Azacitidine Regimens Compared to Crs with 7+3 Induction Chemotherapy and the Effect on Overall Survival.
Blood.
2016
-
Cost-Effectiveness of Blood Transfusions Versus Observation for Silent Cerebral Infarcts from the Silent Cerebral Infarct Trial.
Blood.
2016
-
Current Diagnosis Patterns for Acute Myeloid Leukemia (AML) in Clinical Practice Compared with World Health Organization (WHO) 2008 Recommendations: Outcomes from the CONNECT (R) Myelodysplastic Syndromes (MDS) and AML Disease Registry.
Blood.
2016
-
Durable Overall Survival Benefit in Patients >= 60 Years with Relapsed or Refractory AML Treated with Vosaroxin/Cytarabine Vs Placebo/Cytarabine: Updated Results from the Valor Trial.
Blood.
2016
-
EGF Accelerates Hematopoietic Stem Cell Regeneration Following 5-FU Chemotherapy Via G-CSF Receptor Signaling.
Blood.
2016
-
ENESTgoal Treatment-Free Remission Study: Updated Preliminary Results and Digital Polymerase Chain Reaction Analysis in Patients with Chronic Myeloid Leukemia in Chronic Phase Who Switched from Imatinib to Nilotinib.
Blood.
2016
-
Effect of FXIII Polymorphism on Formation of Heterocellular Aggregates in SCD.
Blood.
2016
-
Feasibility of Allogeneic Hematopoietic Cell Transplantation Among High-Risk AML Patients in First Complete Remission: Results of the Transplant Objective from the SWOG (S1203) Randomized Phase III Study of Induction Therapy Using Standard 7+3 Therapy or Idarubicin with High-Dose Cytarabine (IA) Versus IA Plus Vorinostat.
Blood.
2016
-
Final Results of the Chrysalis Trial: A First-in-Human Phase 1/2 Dose-Escalation, Dose-Expansion Study of Gilteritinib (ASP2215) in Patients with Relapsed/ Refractory Acute Myeloid Leukemia (R/R AML).
Blood.
2016
-
Fingolimod Is Cytotoxic in Acute Myeloid Leukemia Independent of Additional Chemotherapeutic Agents.
Blood.
2016
-
Impact of Wait Times for Autologous Stem Cell Transplantation in Patients with Aggressive Non-Hodgkin Lymphoma, a Subset Analysis of the Canadian Cancer Trials Group (CCTG) LY.12 Clinical Trial.
Blood.
2016
-
Improved Prognostic Significance of Genomic and Transcriptional Biomarkers By Examining Enriched Populations of AML Blasts: A SWOG Report.
Blood.
2016
-
Long Term Survival and Clinical Complete Responses of Various Prognostic Subgroups in 103 Relapsed/Refractory Acute Myeloid Leukemia(r/r AML) Patients Treated with Guadecitabine (SGI-110) in Phase 2 Studies.
Blood.
2016
-
Mechanism of Complement Activation By PF4/ Heparin Complexes.
Blood.
2016
-
Novel ELISA-Based Assay for Detection of Complement Activation By PF4/Heparin Complexes.
Blood.
2016
-
Physician Factors Determining Treatment Decisions in Selecting Second Line Agents for Pediatric ITP.
Blood.
2016
-
Postoperative Venous Thromboembolism in Children Is Increased in Setting of Cancer or Infection.
Blood.
2016
-
Prospective Implementation of Multi-Disciplinary Obstetric Team Decreases the Mortality Rate of Pregnant Women with Sickle Cell Disease in Ghana.
Blood.
2016
-
RNA Aptamer Against FXa Synergizes with FXa Catalytic Site Inhibitors to Effectively and Reversibly Anticoagulate Blood in an Ex Vivo Oxygenator Circuit.
Blood.
2016
-
Results from Ongoing Phase 2 Trial of SL-401 As Consolidation Therapy in Patients with Acute Myeloid Leukemia (AML) in Remission with High Relapse Risk Including Minimal Residual Disease (MRD).
Blood.
2016
-
Results from Phase 2 Trial Ongoing Expansion Stage of SL-401 in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN).
Blood.
2016
-
Results of a Clinical Study of Pevonedistat (Pev),a First-in-Class NEDD8-Activating Enzyme (NAE) Inhibitor, Combined with Azacitidine (Aza) in Older Patients (Pts) with Acute Myeloid Leukemia (AML).
Blood.
2016
-
Ruxolitinib Used to Treat Hypereosinophilic Syndrome.
Blood.
2016
-
SWOG S1203: A Randomized Phase III Study of Standard Cytarabine Plus Daunorubicin (7+3) Therapy Versus Idarubicin with High Dose Cytarabine (IA) with or without Vorinostat (IA plus V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML).
Blood.
2016
-
Short Course of Bendamustine and Rituximab Followed By 90Y-Ibritumomab Tiuxetan in Patients with Chemotherapy-Naive Follicular Lymphoma (FOL-BRITe): Final Report of Response Rates and Progression Free Survival.
Blood.
2016
-
Simultaneous Measurement of Cerebral Blood Flow and Arterial Transit Time for Sickle Cell Disease.
Blood.
2016
-
Successful Engraftment of Donor Umbilical Cord Blood (UCB) Cells after Co-Transplantation of Nicord (R) (Ex Vivo Expanded UCB Progenitor Cells with Nicotinamide) and a Second Unmanipulated Cord Blood Unit after Myeloablative Chemotherapy in Pediatric Patients with Severe Sickle Cell Disease.
Blood.
2016
-
Surface CD5 Protein Risk Stratifies Chronic Lymphocytic Leukemia.
Blood.
2016
-
Three Factor Prothrombin Complex Concentrates in Cardiac Surgery: A Novel Algorithmic Approach to Perioperative Bleeding.
Blood.
2016
-
Toxicities and Related Outcomes of Elderly Patients (pts) (>= 65 Years) with Hematologic Malignancies in the Contemporary Era (Alliance A151611).
Blood.
2016
-
Transformation in Pre-Treatment Presentations of Gaucher Disease during the First Two Decades of Imiglucerase Enzyme Replacement Therapy: A Report from the International Collaborative Gaucher Group Gaucher Registry.
Blood.
2016
-
Umbilical Cord Blood (UCB) Transplantation in Children with Acute Leukemia: Impact of Conditioning Regimen on Transplant Outcomes.
Blood.
2016
-
Use of Mobile Technology to Monitor Pain and Reduce Outpatient, Emergency Department (ED), and Hospital Visits for Sickle Cell Pain Crisis.
Blood.
2016
-
Vadastuximab Talirine Monotherapy in Older Patients with Treatment Naive CD33-Positive Acute Myeloid Leukemia (AML).
Blood.
2016
-
Vadastuximab Talirine Plus Hypomethylating Agents: A Well-Tolerated Regimen with High Remission Rate in Frontline Older Patients with Acute Myeloid Leukemia (AML).
Blood.
2016
-
Variation in Serial TCD Velocity Measurements in the TCD with Transfusions Changing to Hydroxyurea (TWiTCH) Trial.
Blood.
2016
-
Von Willebrand Factor to Prevent Postpartum Hemorrhage.
Blood.
2016
-
A Phase 1 Trial of SGN-CD33A As Monotherapy in Patients with CD33-Positive Acute Myeloid Leukemia (AML).
Blood.
2015
-
Additional Analyses of a Randomized Phase II Study of Azacitidine Combined with Lenalidomide or with Vorinostat Vs. Azacitidine Monotherapy in Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML): North American Intergroup Study SWOG S1117.
Blood.
2015
-
Antileukemic Activity and Tolerability of ASP2215 80mg and Greater in FLT3 Mutation-Positive Subjects with Relapsed or Refractory Acute Myeloid Leukemia: Results from a Phase 1/2, Open-Label, Dose-Escalation/Dose-Response Study.
Blood.
2015
-
Baseline Predictors of Mortality in Patients with Relapsed or Refractory Acute Myeloid Leukemia Treated with Vosaroxin Plus Cytarabine or Placebo Plus Cytarabine in the Phase 3 VALOR Study.
Blood.
2015
-
Defining the Genomic Make up of Acute Myeloid Leukemia in Adolescents and Young Adults (AYA): Report from COG AAML03P1, AAML531 and SWOG S0106.
Blood.
2015
-
Development of an Online Patient Decision Aid for Previously Treated Mantle Cell Lymphoma.
Blood.
2015
-
Early Allogeneic Stem Cell Transplantation and Use of Asparaginase during Induction Chemotherapy Appear to Improve Otherwise Poor Outcomes in Adult T Cell Acute Lymphoblastic Leukemia/Lymphoma (T-ALL/T-LBL) Patients: A Multi Institutional Review.
Blood.
2015
-
Effect of Minimal Residual Disease (MRD) Information on Prediction of Relapse and Survival in Adult Acute Myeloid Leukemia.
Blood.
2015
-
Health Care Utilization and End of Life Care for Older Patients with Acute Myeloid Leukemia Receiving Supportive Care Alone.
Blood.
2015
-
Impact of Available Therapies on Survival of Very Elderly Myelodysplastic Syndrome (MDS) Patients (Age above 75 yrs).
Blood.
2015
-
Molecular Characterization of 140 Patients in the Pyruvate Kinase Deficiency (PKD) Natural History Study (NHS): Report of 20 New Variants.
Blood.
2015
-
Multi-Center US Intergroup Study of Intensive Chemotherapy Plus Dasatinib Followed By Allogeneic Stem Cell Transplant in Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Younger Than 60.
Blood.
2015
-
Multiple Myeloma Patient Experience with Financial Toxicity: Findings from the Cancer Experience Registry.
Blood.
2015
-
North American Cooperative Group Members' Patterns of Blood Products Transfusion for Patients with Acute Leukemia.
Blood.
2015
-
Outcomes for Older Patients with Acute Myeloid Leukemia Admitted to the Intensive Care Unit.
Blood.
2015
-
Potentially Avoidable Hospitalizations in Older Patients with Acute Myeloid Leukemia (AML).
Blood.
2015
-
Prognostic Methylation Markers for Survival in Cytogenetically Normal AML Patients Treated on SWOG Trials.
Blood.
2015
-
Rapid Achievement of MR4.5 after Switching from Imatinib (IM) to Nilotinib (NIL) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Preliminary Results from ENESTgoal.
Blood.
2015
-
Report of the Relapsed/Refractory Cohort of SWOG S0919: A Phase 2 Study of Idarubicin and Cytarabine in Combination with Pravastatin for Acute Myelogenous Leukemia.
Blood.
2015
-
SGN-CD33A Plus Hypomethylating Agents: A Novel, Well-Tolerated Regimen with High Remission Rate in Frontline Unfit AML.
Blood.
2015
-
Symptom Burden, Quality of Life, and Distress in Acute Myeloid Leukemia Patients Receiving Induction Chemotherapy: Results of a Prospective Electronic Patient-Reported Outcomes Study.
Blood.
2015
-
TCD with Transfusions Changing to Hydroxyurea (TWiTCH): Hydroxyurea Therapy As an Alternative to Transfusions for Primary Stroke Prevention in Children with Sickle Cell Anemia.
Blood.
2015
-
The Phenotypic Spectrum of Pyruvate Kinase Deficiency (PKD) from the PKD Natural History Study (NHS): Description of Four Severity Groups By Anemia Status.
Blood.
2015
-
The Spectrum of Alpha-Spectrin Associated Hereditary Spherocytosis.
Blood.
2015
-
A Randomized Phase II Study of Azacitidine Combined with Lenalidomide or with Vorinostat Vs. Azacitidine Monotherapy in Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML): North American Intergroup Study SWOG S1117.
Blood.
2014
-
Clinician Approaches to Myeloma in Academia and the Community : An in-Practice Qualitative Study.
Blood.
2014
-
Empiric Definition of Eligibility Criteria for Clinical Trials in Relapsed/Refractory AML: Analysis of 1,892 Patients from HOVON/SAKK and SWOG.
Blood.
2014
-
Favorable Outcomes for Older Adolescents and Young Adults (AYA) with Acute Lymphoblastic Leukemia (ALL): Early Results of US Intergroup Trial C10403.
Blood.
2014
-
Growing Pains - Determination of Transfer and Transition from Pediatrics to Adult Outpatient Clinics for Patients with Sickle Cell Disease (SCD).
Blood.
2014
-
Improved Survival in Patients with First Relapsed or Refractory Acute Myeloid Leukemia (AML) Treated with Vosaroxin Plus Cytarabine Versus Placebo Plus Cytarabine: Results of a Phase 3 Double-Blind Randomized Controlled Multinational Study (VALOR).
Blood.
2014
-
Interim Analysis of a Phase 1 Trial of SGN-CD33A in Patients with CD33-Positive Acute Myeloid Leukemia (AML).
Blood.
2014
-
Pevonedistat (MLN4924), an Investigational, First-in-Class NAE Inhibitor, in Combination with Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML) Considered Unfit for Conventional Chemotherapy: Updated Results from the Phase 1 C15009 Trial.
Blood.
2014
-
Post-Transplant Cyclophosphamide Following Myeloablative Peripheral Blood Stem Cell Transplantation: A Single Institutional Experience.
Blood.
2014
-
Alteration Of Cytogenetic Risk Stratification In New Diagnosis Of Leukemia By FISH Testing - Retrospective Review Of The SWOG Experience.
Blood.
2013
-
Azacitidine With Or Without Entinostat For The Treatment Of Therapy-Related Myeloid Neoplasm: Further Results Of The E1905 North American Leukemia Intergroup Study.
Blood.
2013
-
Frontline-Treatment Of Acute Lymphoblastic Leukemia (ALL) In Older Adolescents and Young Adults (AYA) Using a Pediatric Regimen Is Feasible: Toxicity Results of the Prospective US Intergroup Trial C10403 (Alliance).
Blood.
3903-3906.
2013
-
MLN4924, a Novel Investigational Inhibitor Of NEDD8-Activating Enzyme (NAE), In Adult Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS): Results From Multiple Dosing Schedules In a Phase 1 Study.
Blood.
2013
-
Palliative Care For Patients With Hematologic Malignancies: A Profile Of Patients With Blood Cancers Referred To The Choice Hospice Network.
Blood.
2013
-
A Phase II Trial of Azacitidine (NSC-102816) and Gemtuzumab Ozogamicin (NSC-720568) As Induction and Post-Remission Therapy in Patients of Age 60 and Older with Previously Untreated Non-M3 Acute Myeloid Leukemia (SWOG S0703): Report On the Poor Risk Patients.
Blood.
2012
-
CD38 Variation in Chronic Lymphocytic Leukemia.
Blood.
2012
-
Declining Rates of Treatment-Related Mortality in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Given "Intensive" Induction Regimens: A Report From the Southwest Oncology Group (SWOG) and MD Anderson Cancer Center (MDA).
Blood.
2012
-
Incidence, Treatment, and Consequences of Chemotherapy-Induced Febrile Neutropenia in Inpatient and Outpatient Settings.
Blood.
2012
-
The Metabolic Signature of CLL: Enhanced Glucose Metabolism in A Subset of High-Risk CLL Patients.
Blood.
2012
-
Timing of the Initiation of Hydroxyurea and Hematologic Outcomes in Patients with Sickle Cell Disease (SCD).
Blood.
2012
-
Prevalence of MBL Increases Over Time In Relatives of CLL Families.
Blood.
1659-1659.
2011
-
Prognostic Significance of FLT3 and NPM1 Mutations in Adults of Age 18-60 with De Novo Acute Myeloid Leukemia (AML) on SWOG S0106 Study: A Study by FHCRC and SWOG.
Blood.
1080-1080.
2011
-
Race As a Determinant of Disease Biology and Outcomes in Chronic Lymphocytic Leukemia.
Blood.
778-779.
2011
-
Safety and Tolerability of Plerixafor in Combination with Cytarabine and Daunorubicin in Patients with Newly Diagnosed Acute Myeloid Leukemia-Preliminary Results From a Phase I Study.
Blood.
39-40.
2011
-
Sirolimus Inhibits Proliferation but Enhances Suppressive Activity of Rhesus Macaque Natural CD4 Regulatory T Cells.
Blood.
461-461.
2011
-
The Impact of Factor IX Level on Thrombin Generation and Bleeding During Warfarin Anticoagulation.
Blood.
250-250.
2011
-
The Role of Surface Immunoglobulin Isotype in Chronic Lymphocytic Leukemia Disease Biology and Clinical Outcome.
Blood.
1229-1229.
2011
-
A 10 Day Schedule of Azacitidine Induces More Complete Cytogenetic Remissions Than the Standard Schedule In Myelodysplasia and Acute Myeloid Leukemia with Myelodysplasia-Related Changes: Results of the E1905 US Leukemia Intergroup Study.
Blood.
1636-1636.
2010
-
A Retrospective Multi-Center Analysis of Prognostic Factors Determining Outcomes In Patients with Secondary AML..
Blood.
883-884.
2010
-
Allogeneic Hematopoietic Stem Cell Transplantation with Clofarabine/Busulfan x 4 (CloBu4) Conditioning Exhibits Significant Anti-Tumor Activity In Non - Remission Hematologic Malignancies, Especially In AML.
Blood.
20-21.
2010
-
Complications of Implantable Venous Access Devices In Patients with Sickle Cell Disease.
Blood.
692-692.
2010
-
Hydroxyurea Reduces Conversion From Conditional to Abnormal TCD Velocities In Children with Sickle Cell Anemia (SCA).
Blood.
123-124.
2010
-
Identification of a Costimulation Blockade Resistant Mechanism of Bone Marrow Allograft Rejection Induced by Infection with a Murine EBV Homologue..
Blood.
625-625.
2010
-
Pre-Clinical and Interim Results of a Phase II Trial of Perifosine In Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL).
Blood.
768-769.
2010
-
Prolonged Administration of Azacitidine with or without Entinostat Increases Rate of Hematologic Normalization for Myelodysplastic Syndrome and Acute Myeloid Leukemia with Myelodysplasia-Related Changes: Results of the US Leukemia Intergroup Trial E1905.
Blood.
264-265.
2010
-
Reduced Intensity Conditioning In Children Undergoing Unrelated Umbilical Cord Blood Transplantation for Non-Malignant Diseases: Preliminary Results Demonstrate a High Rate of Engraftment and Low Incidence of Gvhd..
Blood.
1453-1454.
2010
-
Six Year, Single Institution, off-Label Use of Recombinant Factor VIIa..
Blood.
603-603.
2010
-
The Novel, Investigational NEDD8-Activating Enzyme Inhibitor MLN4924 In Adult Patients with Acute Myeloid Leukemia (AML) or High-Grade Myelodysplastic Syndromes (MDS): A Phase 1 Study.
Blood.
288-288.
2010
-
A Pathobiological Role of the Insulin Receptor in Chronic Lymphocytic Leukemia.
Blood.
918-918.
2009
-
Amonafide L-Malate (AS1413) in Combination with Cytarabine Is Equally Effective in Older and Younger Patients with Secondary Acute Myeloid Leukemia (AML); Final Data From a Phase II Study..
Blood.
433-434.
2009
-
Complete Response to Clofarabine Is Durable and Correlates with Survival in Previously Untreated Older Adult Patients with Acute Myeloid Leukemia (AML) and Unfavorable Prognostic Factors.
Blood.
814-814.
2009
-
Family-Associated Monoclonal B Lymphocytosis Shows Differences From CLL That Suggest An Indolent Biology.
Blood.
511-511.
2009
-
Genome-Wide Analysis of Microdeletions and Identification of NF1 Inactivation in Acute Myelogenous Leukemia..
Blood.
73-74.
2009
-
Molecular Profiling Identifies Plasmablasts as the Cells of Origin of Activated Diffuse Large B Cell Lymphoma.
Blood.
257-257.
2009
-
Monosomal Karyotype Is Predictive of Poor Response to Therapy and Worse Overall Survival in Secondary Acute Myeloid Leukemia (sAML); Analysis of a Multi-Center Phase II Study of Amonafide and Cytarabine Induction Therapy.
Blood.
819-820.
2009
-
Phase II Study of the Oral MEK Inhibitor AZD6244 in Advanced Acute Myeloid Leukemia (AML).
Blood.
821-822.
2009
-
Preliminary Results of Southwest Oncology Group Study S0106: An International Intergroup Phase 3 Randomized Trial Comparing the Addition of Gemtuzumab Ozogamicin to Standard Induction Therapy Versus Standard Induction Therapy Followed by a Second Randomization to Post-Consolidation Gemtuzumab Ozogamicin Versus No Additional Therapy for Previously Untreated Acute Myeloid Leukemia.
Blood.
326-327.
2009
-
Prevention of Acute GvHD During MHC Haploidentical BMT: Evaluating the Efficacy of T-Cell Costimulation Blockade Using a Novel Rhesus Macaque Transplant Model..
Blood.
968-969.
2009
-
Results From a Randomized Trial of Salvage Chemotherapy Followed by Lestaurtinib for FLT3 Mutant AML Patients in First Relapse.
Blood.
325-326.
2009
-
Single-Agent Clofarabine Produces Durable Remissions in Patients with Acute Myelogenous Leukemia (AML) Who Are >= 70, Have Intermediate or Unfavorable Cytogenetics, Antecedent Hematological Disorders (AHD), or 2 or More Unfavorable Prognostic Factors.
Blood.
822-823.
2009
-
The Complex Relationship Between Sickle Cell Disease and Depression.
Blood.
1014-1015.
2009
-
Transplantation Following Myeloablative Cytoreduction Results in Excellent Survival, Long-Term Engraftment, and Donor Chimerism in Children with Chronic Granulomatous Disease Across Donor and Graft Sources.
Blood.
1319-1319.
2009
-
Comprehensive Ultra High Resolution Analysis of Copy Number and Allele Status Including Novel Microdeletions Spanning NF1 in Acute Myelogenous Leukemia.
Blood.
1066-1066.
2008
-
Identification of p53 Aberration-Dependent as Well as Non-p53-Mediated Resistance to MDM2 Inhibitors in Acute Myelogenous Leukemia.
Blood.
569-569.
2008
-
Myeloablative Conditioning with Clofarabine and Busulfan X 4 (CloBu4) Is Well Tolerated, Facilitates Secure Engraftment, and Exhibits Significant Anti-Tumor Activity against Non-Remission Hematologic Malignancies Including AML.
Blood.
749-749.
2008
-
Phase II Study of Single Agent Clofarabine in Previously Untreated Older Adult Patients with Acute Myelogenous Leukemia (AML) Unlikely to Benefit from Standard Induction Chemotherapy.
Blood.
209-209.
2008
-
Prevention of Acute GvHD during Haplo-BMT: Evaluating the Efficacy of T-Cell Costimulation Blockade Using a Novel Rhesus Macaque Transplant Model.
Blood.
1207-1207.
2008
-
Single Donor 4/6 Matched Banked Unrelated Cord Blood Is An Effective Graft Source for Children Undergoing Myeloablative Transplantation for Malignant and Nonmalignant Disorders: Single Center Analysis of 318 Patients.
Blood.
690-690.
2008
-
Analysis of the cellular components of the graft and clinical characteristics of 159 children with lysosomal and peroxisomal disorders (LSD) undergoing unrelated umbilical cord blood transplantation at a single center.
Blood.
106A-106A.
2007
-
Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia.
Blood.
73A-73A.
2007
-
Functional and numerical T cell abnormalities in chronic lymphocytic leukemia.
Blood.
908A-908A.
2007
-
Further investigation of the role of factor XIII in priapism associated with SCD.
Blood.
998A-998A.
2007
-
Genomic complexity identifies patients with agressive chronic lymphocytic leukemia..
Blood.
151A-151A.
2007
-
Inhibition of nitric oxide synthase (NOS) 1, NOS2, and NOS3 enzymatic activities by vitamin B-12 and related corrins: Biochemical and molecular modeling studies.
Blood.
783A-783A.
2007
-
Integrated genomic profiling of chronic lymphocytic leukemia identifies subtypes of deletion 13q14 with differential expression of LATS2.
Blood.
617A-617A.
2007
-
Phase II studies of different schedules and doses of the farnesyl transferase inhibitor tipifarnib (R115777, zarnestra, NSC-702818) for patients of age 70 or older with previously untreated acute myeloid leukemia (AML): A north American intergroup study (S0432).
Blood.
136A-136A.
2007
-
The effects of chronic opiates pain therapy in sickle cell anemia.
Blood.
997A-997A.
2007
-
The relationship of opiate analgesia to quality of life in an adult sickle cell population.
Blood.
670A-670A.
2007
-
A phase II trial of combination therapy with arsenic trioxide (ATO) and gemtuzumab ozogamicin (GO) in patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) arising from MDS..
Blood.
754A-754A.
2006
-
Changes in the pattern of cytogenetic aberrations with advancing age in acute myeloid (Non-APL) leukemia: A Southwest Oncology study (S9007)..
Blood.
242A-242A.
2006
-
DEAH-box splicing factor gene, prp16 amplification in acute myeloid leukemia..
Blood.
198B-198B.
2006
-
Defibrotide (DF) for the treatment of severe veno-occlusive disease (sVOD) and multi-organ failure (MOF) post SCT: Final results of a multi-center, randomized, dose-finding trial..
Blood.
17A-18A.
2006
-
Genomic profiling of chronic lymphocytic leukemia identifies novel genetic subtypes..
Blood.
592A-592A.
2006
-
Inhibition of TLX3 and NKX2-5 in t(5;14)(q35;q32) T-ALL after blocking remote 3'-BCL11B enhancer sequences with matching DNA oligos reveals coregulation by PU.1 and HMGA1..
Blood.
627A-627A.
2006
-
Melphalan containing cytoreduction results in a good overall survival (OS) in pediatric patients with relapse or refractory AML undergoing unrelated umbilical cord blood transplantation (UCBT)..
Blood.
899A-899A.
2006
-
Prospective analysis of TEL and MLL gene rearrangements in childhood acute lymphoblastic leukemia: A Children's Oncology Group study..
Blood.
68A-69A.
2006
-
Restoring initial thrombin generation does not normalize cutaneous wound healingin hemophilia B..
Blood.
306A-306A.
2006
-
Tissue factor is absent from sites of cutaneous wounds: Implications for bleeding in hemophilia..
Blood.
511A-512A.
2006
-
A randomized, open-label study of Lestaurtinib (CEP-701), an oral FLT3 inhibitor, administered in sequence with chemotherapy in patients with relapsed AML harboring FLT3 activating mutations: Clinical response correlates with successful FLT3 inhibition..
Blood.
121A-121A.
2005
-
Combination of datmorubicin and cytarabine chemotherapy with gemtuzumab ozogamicin as initial therapy for elderly patients with previously untreated acute myeloid leukemia..
Blood.
238B-238B.
2005
-
Delayed wound healing in hemophilia B mice..
Blood.
894A-894A.
2005
-
Partially HLA matched, non-myeloablative allogeneic transplantation.
Blood.
812A-812A.
2005
-
Reaction of fibrinogen with homocysteine thiolactone mimics the dysfibrinogenemia produced by hyperhomocysteinemia..
Blood.
44A-44A.
2005
-
COAT platelet formation is P2Y 12-dependent.
Blood.
437A-438A.
2004
-
Gemtuzumab ozogamicin (Mylotarg (R)) as primary induction therapy for elderly patients with acute myeloid leukemia: A phase II trial.
Blood.
210B-210B.
2004
-
Intense immunochemotherapy (IC) and autologous stem, cell transplant (ASCT) for untreated patients (pts) with mantle cell lymphoma (MCL): CALGB 59909. A preliminary report..
Blood.
255A-256A.
2004
-
A single cell analysis of immunoglobulin genes in chronic lymphocytic leukemia (CLL): Progressive somatic mutations in the immunoglobulin heavy and light chains contribute to intraclonal diversification in CLL..
Blood.
666A-666A.
2003
-
Chronic lymphocytic leukemia cells (CLL) express the neuronal isoform of nitric oxide synthase (NOS1), and NOS1-specific inhibitors induce CLL cell death..
Blood.
353B-353B.
2003
-
Hematopoietic stem cell dose correlates with the speed of immune reconstitution after stem cell transplantation..
Blood.
396B-396B.
2003
-
Platelets stimulated with convulxin plus thrombin develop platelet subpopulations with increased binding of factor VIII, factor IX, and factor X..
Blood.
293A-293A.
2003
-
Protein phosphatase inhibitors as potent cytotoxic agents for B-cell CLL in vitro..
Blood.
360B-360B.
2003
-
Risk assessment for hepatic veno-occlusive disease in patients treated with gemtuzumab ozogamicin (Mylotarg (R)) with or without hematopoietic stem cell transplantation..
Blood.
871A-871A.
2003
-
Chronic lymphocytic leukemia (CLL) cell CD38 expression and inducible nitric oxide synthase (NOS2) expression are associated with serum IL-4 levels..
Blood.
357B-357B.
2002
-
Elevated expression of numerous interferon inducible genes in primary bone marrow cells expressing p185 Bcr-Abl versus p210 Bcr-Abl by DNA microarray analysis..
Blood.
584A-584A.
2002
-
Final results of a multivariate logistic regression analysis to determine factors contributing to the risk of developing hepatic veno-occlusive disease (VOD) following treatment with gemtuzumab ozogamicin..
Blood.
339A-339A.
2002
-
Immunophenotypic and functional characterization of CD4+ CD25+ regulatory T cells as a function of aging in normal human peripheral blood and autoimmune disease..
Blood.
250A-250A.
2002
-
Preliminary analysis of a randomized phase 2 study of the safety and efficacy of 1 vs. 2 doses of gemtuzumab ozogamicin (Mylotarg (R)) in patients with high risk myelodysplastic syndrome..
Blood.
795A-795A.
2002
-
High dose factor VIIa enhances clot stability in a model of hemophilia..
Blood.
826A-827A.
2001
-
Hyperhomocysteinemia induces alterations in fibrinogen function and fibrin clot structure in a rabbit model..
Blood.
39A-39A.
2000
-
Hyperhomocysteinemia induces monocyte tissue factor (TF) expression in vivo..
Blood.
32B-32B.
2000
-
Prolonged disease-free survival in patients with acute myeloid leukemia in first relapse treated with gemtuzumab ozogamicin (Mylotarg (TM), CMA-676) followed by hematopoietic stem cell transplantation..
Blood.
320A-320A.
2000
-
Activated protein C (APC) functions by inhibiting initiation of coagulation rather than by terminating a hemostatic response..
Blood.
224A-224A.
1999
-
De-encryption of cellular tissue factor is independent of its cytoplasmic domain..
Blood.
227A-227A.
1999
-
Efficacy and safety of CMA-676 in patients with AML in first relapse..
Blood.
696A-696A.
1999
-
The initial rate, but not the total amount, of thrombin (IIa) generated determines fibrin clot structure in a cell-based model of coagulation..
Blood.
230A-231A.
1999
-
Tissue factor independent effect of high dose factor VIIa directly correlates with factor X levels..
Blood.
228A-228A.
1999